Transaction details
Steven P. Coen, the chief financial officer of Ginkgo Bioworks Holdings, Inc. (NASDAQ:DNA), sold 324 shares of the company’s Class A Common Stock on April 17, 2026. The filing shows the trade was executed at $7.952 per share, amounting to approximately $2,576 in proceeds.
Reason for sale
The filing specifies the disposition was a "sell to cover" tied to tax withholding obligations arising from the vesting of restricted stock and/or restricted stock units. It notes the transaction did not represent a discretionary sale by Mr. Coen and that the company’s equity incentive plans permit such sell-to-cover actions to satisfy tax liabilities associated with equity compensation.
Related equity activity
On April 16, 2026, the filing reports Mr. Coen received 743 shares through the vesting of restricted stock units, broken into tranches of 587 and 156 shares. Each restricted stock unit entitles the holder to one share of the issuer’s Class A Common Stock upon vesting. Following the April 16 and April 17 filings, Mr. Coen directly owns 50,268 shares of Class A Common Stock.
In addition to his direct holdings, Mr. Coen retains derivative securities in the form of restricted stock units, with 7,644 units and 3,599 units outstanding. The filing indicates these RSU tranches vest over time, with one batch scheduled to vest in monthly installments after May 1, 2024, and another batch also vesting in monthly installments after May 1, 2024.
Market context
The insider activity coincides with a recent run-up in Ginkgo Bioworks’ share price. The company’s stock rose 20 percent over the prior week and was trading at $7.98 at the time referenced in the filing. An InvestingPro review cited in the earlier filing characterizes the shares as appearing undervalued at current levels and notes recent momentum.
Operational and strategic developments
Ginkgo reported fourth-quarter 2025 results that highlighted notable improvements in cash management and operational restructuring. While revenue from the cell engineering segment declined, the company reduced operating losses and curtailed cash burn through aggressive cost-cutting measures, according to the report.
The company also unveiled the Ginkgo Cloud Lab, a web-based platform that allows researchers remote access to Ginkgo’s automated laboratory infrastructure. The platform runs on Reconfigurable Automation Carts, creating a modular laboratory environment equipped with more than 70 instruments for a range of biological operations.
Analyst action and automation roadmap
BTIG adjusted its price target for Ginkgo Bioworks to $5.00 from $9.00 and maintained a Sell rating. The brokerage’s revision followed the company’s emphasis on developing Autonomous Labs scheduled for 2026. Ginkgo intends to expand its RAC cart automation within its Boston facility, aiming to double the number of systems by the end of 2026. Those moves are described as part of a strategic pivot toward automation and strengthened financial management.
Note on content
The article presents the details contained in the most recent regulatory filing and company disclosures regarding executive stock activity and corporate developments.